London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3rd Annual Regen Med Investor Day, being held Wednesday, March 25, 2015 in New York City.
Dr. Blake will present at 2:40pm ET / 6.40pm GMT to attending investors. During his presentation Dr. Blake will discuss Oxford BioMedica’s expertise in the clinical development and manufacturing of gene and cell therapies.
Details of the Oxford BioMedica presentation are as follows:
Event: ARM’s Regen Med Investor Day
Date: March 25, 2015
Time: 2.40pm ET / 6.40pm GMT
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcastand will be published on the event’s website shortly after the conference as well as on the company’s website in the media section: http://www.oxfordbiomedica.co.uk/webcasts-and-audio/.
- Ends -
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321